Open Access

Multiple functions of hypoxia-regulated miR-210 in cancer

Journal of Experimental & Clinical Cancer Research201433:50

https://doi.org/10.1186/1756-9966-33-50

Received: 11 May 2014

Accepted: 1 June 2014

Published: 9 June 2014

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression post-transcriptionally. miRNAs can be induced by a variety of stresses such as hypoxia, and are involved in diverse biological processes including differentiation, cell proliferation, cell death, and tumorigenesis. Hypoxia, a common feature of tumor microenvironment, can induce a number of miRNAs expression. miRNA-210 (miR-210) is one of the hypoxia-regulated-miRNAs, which has been investigated extensively in cancer. However, paradoxically opposing results were documented regarding whether it is an oncogene or a tumor suppressor, and whether it is a positive or negative prognostic biomarker. In the present review, we focus on the following investigations of miR-210: 1) its functions of as an oncogene, 2) its functions as a tumor suppressor, 3) its functions in mitochondrial metabolism, and finally, the diagnostic and prognostic value of miR-210 in cancer researches.

Keywords

microRNA Hypoxia miR-210 Proliferation Apoptosis Angiogenesis Metabolism Diagnosis Prognosis

Introduction

MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression post-transcriptionally by pairing to 3’ untranslated regions (UTRs), coding sequences or 5’ UTRs of target messenger RNAs (mRNAs), which in most cases leads to translation inhibition or mRNA degradation [1]. In mammals, miRNAs are predicted to regulate the activity of approximately 50% of all protein-coding genes [2]. Due to the widespread regulating functions, miRNAs are involved in almost every cellular process including differentiation, cell proliferation, cell death, and tumorigenesis [3].

Hypoxia is a common feature of the tumor microenvironment [4] and has been an extensively investigated field in cancer researches demonstrating its critical role in various physiologic and pathologic processes including cell proliferation, cell survival, angiogenesis, metabolism, tumor invasion and metastasis [5]. It is widely accepted that hypoxia represents an independent adverse prognostic factor in many tumor types [4, 6].

Since the first article demonstrated the functional link between hypoxia and miRNAs expression, which identified a specific hypoxia-regulated miRNAs (HRMs) playing an important role in cell survival in low oxygen environment [7], that more and more HRMs were identified [812]. Although discrepancies exist among HRMs identified by different research groups, the up-regulation of miR-210 induced by hypoxia has been consistent in all published studies in both normal and transformed cells, which implies an essential role of miR-210 for cell adaptation to hypoxia [1315]. Not only in vitro studies correlated miR-210 with hypoxia, in vivo investigation also verified it. In tumor tissues such as breast cancer and head and neck cancers, miR-210 expression levels have been demonstrated to be correlated with hypoxia gene signatures, which suggested a direct connection between miR-210 expression and hypoxia [16, 17].

miR-210 is an intronic miRNA located within the genomic loci of transcript AK123483 [18]. While most studies reported miR-210 regulation in a hypoxia-inducible factor-1 (HIF-1)-dependent way [1921], HIF-2-dependent [22, 23] and HIF-independent [24, 25] regulation of miR-210 have also been reported. The master HRM miR-210 has been investigated intensively, which has identified a variety of functionally important targets involved in cell cycle regulation [18, 22, 2630], cell survival [3136], differentiation [3740], angiogenesis [4151] as well as metabolism [5257].

However, paradoxically opposing results were documented with regard to whether miR-210 is an oncogene or a tumor suppressor, and whether it is a positive or negative prognostic biomarker. In the present review, we focus on the following investigations of miR-210: 1) its functions of as an oncogene, 2) its functions as a tumor suppressor, 3) its functions in mitochondrial metabolism, and finally, the diagnostic and prognostic value of miR-210 in cancer researches.

miR-210 functions as an oncogene

Since miR-210 is up-regulated ubiquitously and robustly in hypoxic cells and hypoxia is a key feature of solid tumors, it is reasonable to explore the functions of miR-210 in tumorigenesis. With the development of bioinformatic miRNA targets prediction tools as well as the improvement of experimental approaches, many diverse targets of miR-210 have been identified, revealing an important role of miR-210 in tumor initiation and progression [58]. Table 1 presents the identified targets of miR-210, showing the oncogenic role of miR-210.
Table 1

Targets of miR-210 functioning as oncogene

Symbol

Description

Related function

Involved cell type

MNT [22]

MAX network transcriptional repressor

Regulate cell proliferation

HCT116

HeLa

HFF-pBABE

ME-180

786-O-pBABE

Casp8ap2 [31]

Caspase 8 associated protein 2

Regulate apoptosis

MSC

PTBP3/ROD1 [61]

Polypyrimidine tract binding protein 3/Regulator of differentiation 1

Regulate apoptosis

HEK-293

HUVEC

E2F3 [32]

E2F transcription factor 3

Regulate apoptosis and cell proliferation

HPASMC

BNIP3 [36]

BCL2/adenovirus E1B 19 kDa interacting protein 3

Induce apoptosis

NPC

PC12

AIFM3 [27]

Apoptosis inducing factor, mitochondrion associated, 3

Induce apoptosis

SMMC-7721

HepG2

HuH7

EFNA3 [41, 64]

Ephrin-A3

Regulate angiogenesis

HUVEC

VMP1 [42]

Vacuole membrane protein 1

Regulate migration and invasion

SMMC-7721

HuH-7

RAD52 [66]

RAD52 homolog (S. cerevisiae)

Involve in DNA repair

HeLa

MCF-7

PTPN1 [68]

protein tyrosine phosphatase, non-receptor type 1

Regulate immune response

IGR-Heu

NA-8

HOXA1 [68]

Homeobox A1

Regulate immune response

IGR-Heu

NA-8

TP53I11 [68]

tumor protein p53 inducible protein 11

Regulate immune response

IGR-Heu

NA-8

Abbreviations: MSC mesenchymal stem cell, HPASMC human pulmonary artery smooth muscle cell, NPCs neural progenitor cell, HUVEC human umbilical vein endothelial cell.

miR-210 promotes cancer cell proliferation

Sustaining proliferative capacity is a key hallmark of cancer cells which acquire such capacity through a number of ways: 1) they may produce growth factor ligands themselves and stimulate normal cells in tumor-associated stroma to supply various growth factors, 2) they may harbor activating mutations to sustain proliferative signaling, and 3) they may disrupt negative-feedback loops that attenuate proliferative signaling [59].

Over the past few years, the role of hypoxia-inducible miR-210 in cell cycle regulation has been a subject of considerable interest and has provided reliable evidence supporting a role for miR-210 in promoting cancer cell proliferation [18, 21, 22, 2630]. Zhang and colleagues [22] identified MNT, a known MYC antagonist, as a miR-210 target. Overexpression of miR-210 can override hypoxia-induced cancer cell cycle arrest and promote cell proliferation by down-regulating MNT directly and activating c-MYC indirectly. Similarly but in a different way, Yang and colleagues [27] demonstrated that downregulation of miR-210 in hypoxic human hepatoma cells induced cell cycle arrest in the G0/G1, resulting in reduced cancer cell proliferation. However, functional targets of miR-210 contributing to such effect require further researches.

miR-210 inhibits apoptosis and protects cancer cell

Hypoxic cancer cells are notorious for their resistance to radiotherapy and many conventional chemotherapeutic agents, of which the underlying mechanisms remain to be revealed [3]. As the master HRM, the association of miR-210 and apoptosis as well as cell survival was intensively investigated. Its antiapoptotic and cytoprotective effects have been demonstrated in many studies involving not only cancer cells [27, 60, 61] but also normal cells such as human pulmonary artery smooth muscle cells (HPASMC) [32], cardiomyocytes [24, 33], bone marrow-derived mesenchymal stem cells (MSCs) [31], as well as neural progenitor cells [36].

Many functional targets of miR-210 associated with apoptosis have been identified, as shown in Table 1. By downregulating the expression of caspase-8-associated protein-2 (Casp8ap2), miR-210 promoted the survival of MSCs that underwent ischemic preconditioning [31]. Through repressing the expression of regulator of differentiation 1 (ROD1), which is also named polypyrimidine tract binding protein 3 (PTBP3), miR-210 reduced the apoptosis of hypoxic cells and increased the survival of hypoxic cells [61]. E2F3, a member of the E2F family of transcriptional factors and a well-known cell cycle regulator, was identified as a direct target of miR-210 in hypoxic HPASMC, its downregulation was shown to be responsible in part for the antiapoptotic effect of miR-210 [32]. Knock down of miR-210 in hypoxic HPASMC, which resulted in concomitant upregulation of E2F3, induced apoptosis without significant change of cell proliferation, indicating the proapoptotic effect of E2F3 as well as the antiapoptotic effect of miR-210 in HPASMC under hypoxia stress [32]. The cytoprotective effect of miR-210 against radiotherapy was also investigated. Overexpression of miR-210 in A549 cell line (non-small cell lung carcinoma-derived cell line) under normoxia can protect cancer cells from radiation [57], while downregulation of miR-210 in hypoxic human hepatoma cells led to increased radiosensitivity, both in vitro and in vivo [27, 62]. As elucidated by Grosso et al., A549 cells stably expressing miR-210 in normoxia exhibited similar radioresistance to A549 cells expressing miR-control in hypoxia, and hypoxia can further increase this resistance. Although the underlying mechanisms responsible for this radioresistance were not fully investigated, the authors gave us a clue that miR-210 expressing cells showed rapid repair of DNA double-strand breaks (DSBs), which might contribute to radioresistance [57]. In addition, synthetic miRNA-Mowers targeting miR-210 in bladder cancer cells can inhibit growth and migration and induce apoptosis [60].

miR-210 regulates angiogenesis, promotes invasion and metastasis

Inducing angiogenesis is another hallmark of cancer, which not only provides nutrients and oxygen, evacuates metabolic wastes and carbon dioxide to sustain cancer cells, but also facilitates metastasis [59]. Many miRNAs have been involved in tumor angiogenesis [44, 63], including miR-21, miR-106a, miR-126, miR-155, miR-182, miR-210 and miR-424.

miR-210 overexpression in normoxic endothelial cells stimulated the formation of capillary-like structures and vascular endothelial growth factor-driven cell migration, while blockade had the opposite effect [41]. Ephrin-A3 (EFNA3) was identified as the direct target, whose down-modulation was necessary for miR-210 mediated stimulation of both tubulogenesis and chemotaxis [41]. Notably, hypoxia can increase the expression of EFNA3 mRNA, so the down-modulation of EFNA3 may attribute to translation inhibition [41]. Another study confirmed EFNA3 as a direct target of miR-210 through luciferase assay, however, upregulation of EFNA3 was shown in ischemia brain, which seemed to be contradictory with the hypothesis that hypoxia induced miR-210 expression would result in downregulation of EFNA3 [64]. Apparently, the unpredictable effects of miR-210 on the expression of EFNA3 need further investigation.

In hypoxic hepatocellular carcinoma (HCC), vacuole membrane protein 1 (VMP1) was identified as the direct and functional downstream target of miR-210, which mediates hypoxia-induced HCC cell migration and invasion [42]. Overexpression of miR-210 in non-invading breast cancer cell line MCF-7 cells led to cell invasion while repression of miR-210 in migrating and invading breast cell line MDA-MB-231 cells resulted in decreased cell migration and invasion [49]. Meanwhile, miR-210 contained in exosomes released by cancer cells can be transported to endothelial cells to induce angiogenesis [50].

miR-210 involves in DNA repair

Genome integrity is of vital importance for normal cells since mutations of crucial genes result in multiple diseases including cancer. Various stresses, including mutagens, ROS, ultraviolet light, radiation as well as chemotherapeutic agents can induce DNA damage, of which DNA double-strand break (DSB) has the most severe effect [65].

Cancer is characterized by genomic instability [59], which may result from hypoxic tumor microenvironment by affecting DNA repair capacity of cancer cells [5]. RAD52, a protein important for DNA DSB repair and homologous recombination, has been identified as a functional target of miR-210 [66]. In addition to down-regulating DNA repair genes, such as RAD52, to increase genomic instability which confers aggressiveness to cancer cells, miR-210 appears to be capable of facilitating DNA DSB repair after radiation exposure, which makes cancer cells more intractable, as demonstrated by Grosso et al. [57]. NSCLC cell lines expressing miR-210 in normoxia are more resistant to radiation due to more effective DNA repair, of which the underlying mechanism remains to be elucidated.

miR-210 induces immunosuppression

During the initiation and development of cancer, cancer cells have acquired multiple mechanisms to evade immunological surveillance. Emerging evidence has shown that certain miRNAs regulate expression of genes that are critically involved in both innate and adaptive immune responses [67]. A recent study investigated the role of miR-210, up-expressed in the hypoxic zones of human tumor tissues, in inducing immunosuppression in hypoxic cancer cells [68]. They examined the susceptibility of IGR-Heu (human NSCLC cell line) and NA-8 (human melanoma cell line) cells in which miR-210 expression had been abrogated by anti-miR-210 to cytotoxic T cells (CTC)-mediated lysis under hypoxia, demonstrated that these cancer cells were more susceptible to CTC-mediated lysis, implying the immunosuppressive effects of miR-210 in hypoxic cancer cells. Functional analysis has identified the potential targets of miR-210, including PTPN1, HOXA1 and TP53I11 that confer immunosuppression to hypoxic cells [68].

miR-210 functions as a tumor suppressor

Controversial to the above cited multiple studies showing that miR-210 acts as an oncogene, many studies suggest that miR-210 can also act as a tumor suppressor, inhibiting tumor initiation. Table 2 summarizes the identified targets of miR-210, implying its potential role as tumor suppressor.
Table 2

Targets of miR-210 functioning as tumor suppressor gene

Symbol

Description

Related function

Involved cell type

E2F3 [18, 21]

E2F transcription factor 3

Regulate apoptosis and cell proliferation

HeLa

ACHN

786-O

Caki2

HEK293

FGFRL1 [19, 26]

fibroblast growth factor receptor-like 1

Regulate cell proliferation

MCF10A

KYSE-170

KYSE-590

PTPN2 [30]

protein tyrosine phosphatase, non-receptor type 2

Regulate cell proliferation

ASC

PIK1 [29]

1-phosphatidylinositol 4-kinase

Regulate mitosis

CNE

HeLa

Cdc25B [29]

cell division cycle 25B

Regulate mitosis

CNE

HeLa

Bub1B [29]

BUB1 mitotic checkpoint serine/threonine kinase B

Regulate mitosis

CNE

HeLa

CCNF [29]

cyclin F

Regulate mitosis

CNE

HeLa

Fam83D [29]

family with sequence similarity 83, member D

Regulate mitosis

CNE

HeLa

Bcl-2 [34]

B-cell CLL/lymphoma 2

Apoptosis

Neuro-2a

Abbreviations: ASC adipose-derived stem cell.

miR-210 induces cell cycle arrest, inhibits cell proliferation, promotes apoptosis

In the study conducted by Giannakakis et al. [18], they found that miR-210 was deleted in 50% of ovarian cancer cell lines and 64% of ovarian cancer samples tested, implying miR-210 as a potential tumor suppressor gene. Subsequent functional analysis identified several targets of miR-210, including E2F3. Contradictory to our foregoing evidence of proapoptotic effect of E2F3 in hypoxia HPASMC, E2F3 was considered as a promoter of cell proliferaion here. Overexpression of miR-210 down-regulated E2F3 expression at the translational level, suggesting that down-regulation of miR-210 expression (such as demonstrated in ovarian cancer due to gene copy aberrations) in hypoxia may increase the expression of E2F3 that promotes cell proliferation and involves in tumorigenesis [18]. However, considering that E2F3 comprises two functionally different forms, E2F3a and E2F3b, with the same 3’ UTR, both E2F3a and E2F3b are targets of miR-210 [18], this interpretation warrants more experiments.

Tsuchiya et al. [26] also demonstrated the anti-proliferative role of miR-210 in cancer. They reported the down-expression of miR-210 in human esophageal squamous cell carcinoma (ESCC) and derived cell lines, and elucidated that overexpression of miR-210 in KYSE-170 (ESCC) cell line not only induces cell cycle arrest in both G0/G1 and G2/M phases, but also causes cell apoptosis and necrosis. Functional analysis identified fibroblast growth factor receptor-like 1 (FGFRL1) as the direct target.

Additional evidence has implicated miR-210 in mitotic regulation. In CNE cells treated with hypoxia mimetic agent, over-expression of exogenous miR-210 significantly decreased cell proliferation, and vice versa [29]. Molecular mechanism analysis revealed that a group of mitosis-related genes, including Plk1, Cdc25B, Cyclin F, Bulb1B and Fam83D, are the direct targets of miR-210, suggesting its inhibitory role on tumor formation.

In addition to inhibiting apoptosis as shown previously, miR-210 can mediate hypoxia-induced apoptosis at least in neuroblastoma cells as demonstrated by Chio et al. [34]. They treated neuro-2a (neuroblastoma cell line) cells with oxygen/glucose deprivation (OGD), elucidated the important role of miR-210 in OGD-induced cell apoptosis, and identified Bcl-2 as the functional target. Overexpression of miR-210 decreased the mRNA and protein levels of Bcl-2, an anti-apoptotic gene, resulting in increased apoptosis.

miR-210 and mitochondrial metabolism

Under hypoxic conditions, cell metabolism shifts from mitochondrial oxidative phosphorylation to glycolysis (the Pasteur effect). HIF-1 plays a critical role in this effect, by up-regulating the expression of most glycolytic enzymes as well as pyruvate dehydrogenase kinase, while down-regulating mitochondrial respiration [69]. As tumors largely rely on glycolysis even under normal oxygen supply (Warburg effect) [59, 70] which is significantly different from normal cells, the underling molecular mechanisms deserve further investigation.

The regulation of mitochondrial metabolism during hypoxia by miR-210 was first reported by Chan et al. [52]. They utilized pulmonary arterial endothelial cells as a representative hypoxic cell type, demonstrated that miR-210 directly targets iron-sulfur cluster assembly proteins (ISCU1/2) and decreases the activity of prototypical iron-sulfur proteins controlling mitochondrial metabolism, including ComplexIand acontiase, resulting in decreased oxidative phosphorylation. Subsequent studies investigating the role of miR-210 in modulating mitochondrial function have revealed more targets of miR-210 [5357]. Besides ISCU [54], which was further confirmed, GPD1L [20], COX10 [53], SDHD and NDUFA4 [55] were also identified as direct targets involved in mitochondrial function regulation. In the study by Puissegur et al. [55], A549 cells overexpressing miR-210 exhibited an aberrant mitochondrial phenotype, mRNA expression profiling analysis linked miR-210 to mitochondrial dysfunction. Interestingly, miR-210 acts not only as a downstream mediator of HIF-1α, it can also promote HIF-1α stability by suppressing GPD1L, producing a positive feedback between HIF-1α and miR-210 [20]. As miR-210 is highly stable, when hypoxic cells undergo reoxygenation, HIF-1α is degraded immediately, but miR-210 remains stable to sustain glycolytic phenotype and inhibit mitochondrial metabolism under normoxia. Such advantage may be utilized by cancer cells, contributing to Warburg effect [57]. Taken together, the above evidence suggests an indisputable role of miR-210 in modulating mitochondrial metabolism, and facilitating adaptation of cancer cells to hypoxic condition.

miR-210 as diagnostic and prognostic biomarker in cancer

Early diagnosis and prognosis evaluation of cancer are of vital importance to improve treatment outcome. It is well acknowledged that cancer cells or tissues harbor aberrant miRNA expression profiles compared to normal cells or tissues, and specific miRNA signature can not only be used for diagnosis but also to classify cancer patients into subgroups with different prognosis guiding individualized treatment [7177]. Many studies have investigated the role of miR-210 in cancer diagnosis and prognosis, however, presenting apparently conflicting results.

Most evidence showed that miR-210 was up-regulated in many solid tumors, including breast cancer [16, 7880], head and neck cancer [17, 76], pancreatic cancer [8183], lung cancer [55, 8487], renal cancer [23, 88, 89], lymphoma [90], osteosarcoma [91], esophageal cancer [92] as well as ovarian cancer [93]. There are also some inconsistent evidence that miR-210 was deleted in some cases of ovarian cancer [18], and was down-regulated in some cases of esophageal cancer [26], exhibiting the complexity and heterogeneity of cancer.

Table 3 enumerates the studies [81, 86, 94100] investigating the diagnostic value of miR-210, either alone or in combination with other miRNAs, providing the sensitivity and specificity of miR-210 when it was used alone to discriminate cancer from non-cancer. Because of the inherent stability of miRNAs [101], and the high sensitivity as well as specificity of quantitative RT-PCR [102], samples used for diagnosis include not only tumor tissue but also serum, plasma, sputum and stool that are more available in clinic, showing the promise of miRNAs in clinical application [103]. Notably, the diagnostic power increased when using multiple miRNAs instead of only one miRNA [81, 86, 9497]. For example, in the study conducted by wang et al. [81], they profiled four pancreatic cancer related miRNAs (miR-21, miR-210, miR-155, miR-196a) as blood-based biomarker for diagnosis. The sensitivity and specificity were 42% to 53% and 73% to 89% respectively, when using only one miRNA for diagnosis, but with the panel of four miRNAs, the sensitivity and specificity increased to 64% and 89% respectively. Other similar studies also showed us similar results [86, 9497].
Table 3

Studies investigating diagnostic value of miR-210

First author

Publication year

Types of cancer

Types of sample

Negative controls

Sensitivity

Specificity

Wang [81]

2009

Pancreatic cancer

plasma

Healthy controls

53%

78%

Xing [86]

2010

Squamous cell LC

sputum

Healthy controls

58%

79%

Shen [94]

2011

Lung cancer

plasma

Benign SPNs

56%

73%

Tan [95]

2011

Squamous cell LC

tissue

Normal lung tissue

Not provided

Not provided

Ren [96]

2012

Pancreatic cancer

stool

Healthy controls

85%

67%

Li [97]

2013

NSCLC

sputum

Healthy controls

Not provided

Not provided

Li [98]

2013

NSCLC

serum

Healthy controls

79%

74%

Zhao [99]

2013

Renal cancer

serum

Healthy controls

81%

79%

Iwamoto [100]

2014

Renal cancer

serum

Healthy controls

65%

83%

Abbreviations: LC lung cancer, NSCLC non-small cell lung cancer, SPN solitary pulmonary nodule.

Table 4 lists the studies [16, 17, 23, 7880, 82, 87, 90, 91, 104107] investigating the prognostic value of miR-210. While most studies documented that high miR-210 expression level in tumor tissue or blood was correlated with poor disease-free and/or overall survival and was a negative prognostic factor, at least three articles investigating soft-tissue sarcoma [104], renal cancer [23] and NSCLC [87] respectively, indicated that miR-210 was a positive prognostic factor. Obviously, the prognostic value of miR-210 expression level in specific cancer type with specific stage varies, and needs more exploration. The interesting study by Buffa et al. presented us an excellent example for exploring miRNAs as prognostic factors for cancer. They conducted comprehensive miRNA and mRNA expression profiling in a large cohort of 207 early-invasive breast cancers. To identify miRNAs with independent prognostic value, they performed penalized Cox regression for distant relapse-free survival (DRFS), including all miRNAs, clinical covariates and gene signatures. At last, they detected four microRNAs to be independently associated with DRFS in estrogen receptor (ER)-positive and six in ER-negative (including miR-210) cases. To further confirm the value of these prognostic miRNAs, they also carried out correlation analysis of these miRNAs with clinicopathologic factors, indicating that miR-210 expression was associated with proliferation, ER positivity, grade, and nodal invasion. In addition, they performed prognostic analysis of pri-miRNAs and predicted target transcripts of prognostic miRNAs, as well as miRNA-processing genes, revealing that identified miRNAs were virtually independent prognostic factors. They also demonstrated that combination of miRNA and target expression could identify patients with the poorest prognosis, showing us the prospect of integrating miRNA and mRNA information for prognosis analysis.
Table 4

Studies investigating prognostic value of miR-210

First author

Publication year

Types of cancer

Types of sample

RR or HR (high VS low expression level)

Camps [16]

2008

Breast cancer

tissue

4.07(PFS), 11.38(OS)

Lawrie [90]

2008

Diffuse large B-cell lymphoma

serum

No significance

Gee [17]

2010

Head and neck cancer

tissue

Not provided

Greither [82]

2010

Pancreatic cancer

tissue

2.48

Buffa [107]

2011

Breast cancer (ER)

tissue

Not provided

Radiojicic [78]

2011

Triple-negative breast cancer

tissue

No significance

Rothe [80]

2011

Breast cancer

tissue

4.43(RFS)

Greither [104]

2012

Soft-tissue sarcoma

tissue

3.19(PFS)*

Toyama [79]

2012

Breast cancer

tissue

4.39

Volinia [105]

2012

Breast cancer

tissue

1.54(OS)

Cai [91]

2013

Pediatric osteosarcoma

tissue

2.6(PFS), 3.3(OS)

Eilertsen [87]

2013

Non-small cell lung cancer

tissue#

1.9(DSS)**

McCormick [23]

2013

Renal cancer

tissue

Not provided

Qiu [106]

2013

Glioblastoma

tissue

0.75**

*intermediate VS high expression level.

#stromal cells in tumor tissues.

**low VS high expression level.

Abbreviations: PFS progression-free survival, OS overall survival, RFS relapse-free survival, DSS disease-specific survival, ER estrogen receptor negative.

Conclusions and future directions

As the master HRM, regulated mainly by HIF-1, miR-210 plays an essential role in hypoxic response. In addition to regulating mitochondrial metabolism, miR-210 is involved in regulating cell cycle, cell survival, differentiation, DNA repair as well as immune response.

Since hypoxia can influence both cell death and survival [108], it is not surprising that miR-210 can act both as an oncogene and a tumor suppressor, depending on cellular context, the extent and duration of hypoxia. A reasonable explanation is that since miRNAs can target hundreds of mRNAs with differential biological functions, the ultimate effect of miR-210 depends on the target mRNAs that are available in certain cells. In addition to multiple targets discussed in this review, many other genes have been identified as miR-210 targets, and more and more potential target genes are emerging [12]. An alternative possibility may be that miR-210 acts as a tumor suppressor at the beginning of tumorigenesis when hypoxia is not significant. However, with the progression of tumor, hypoxia becomes significant, tumor cells evolve, become resistant to hypoxia and adapt well to highly expressed miR-210, then miR-210 switches to an oncogene [19, 29]. Due to the paradoxical functions of miR-210, more investigations are warranted before considering it as an effective therapeutic target in cancer. Future researches should elucidate the specific context that is responsible for specific functions of miR-210. In addition, how to integrate multiple functionally different but related targets of one peculiar miRNA such as miR-210, so as to precisely predict its functions remains a great challenge.

Besides functions of miR-210, we also reviewed the diagnostic and prognostic value of it. As described above, up-regulated miR-210 is not only be detected in cancer tissues, but also in body fluids. It is feasible to discriminate cancer from non-cancer with a specific group of miRNAs including miR-210. However, when it comes to prognosis, it is far too early to use miR-210 alone as a prognostic factor without dispute, and more investigations are needed to elucidate the underlying mechanism of such discrepancy. In future, global analysis of large cohorts of patients with not only miRNAs expression profile but also mRNAs expression profile, even integrated with other genetic information such as DNA copy number variance, single nucleotide polymorphisms, will provide us more insights about significant prognostic factors as well as novel therapeutic targets.

Declarations

Acknowledgements

This study was supported by National Natural Science Foundation of China (Grant no. 81272501). We acknowledge Dr. David L, Roerig for critical reading of the manuscript.

Authors’ Affiliations

(1)
Department of Radiation Oncology, Shandong Cancer Hospital, Shandong University
(2)
Department of Radiation Oncology, Shandong Cancer Hospital, Shandong Academy of Medical Sciences
(3)
Institute of Basic Medicine, Shandong Academy of Medical Sciences

References

  1. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136 (2): 215-233. 10.1016/j.cell.2009.01.002.PubMed CentralPubMedView ArticleGoogle Scholar
  2. Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010, 11 (9): 597-610.PubMedGoogle Scholar
  3. Almeida MI, Reis RM, Calin GA: MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res. 2011, 717 (1–2): 1-8.PubMedView ArticleGoogle Scholar
  4. Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26 (2): 225-239. 10.1007/s10555-007-9055-1.PubMedView ArticleGoogle Scholar
  5. Ruan K, Song G, Ouyang G: Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 2009, 107 (6): 1053-1062. 10.1002/jcb.22214.PubMedView ArticleGoogle Scholar
  6. Begg AC, Stewart FA, Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011, 11 (4): 239-253. 10.1038/nrc3007.PubMedView ArticleGoogle Scholar
  7. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M: A microRNA signature of hypoxia. Mol Cell Biol. 2007, 27 (5): 1859-1867. 10.1128/MCB.01395-06.PubMed CentralPubMedView ArticleGoogle Scholar
  8. Ivan M, Harris AL, Martelli F, Kulshreshtha R: Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med. 2008, 12 (5A): 1426-1431. 10.1111/j.1582-4934.2008.00398.x.PubMed CentralPubMedView ArticleGoogle Scholar
  9. Crosby ME, Devlin CM, Glazer PM, Calin GA, Ivan M: Emerging roles of microRNAs in the molecular responses to hypoxia. Curr Pharm Des. 2009, 15 (33): 3861-3866. 10.2174/138161209789649367.PubMedView ArticleGoogle Scholar
  10. McCormick R, Buffa FM, Ragoussis J, Harris AL: The role of hypoxia regulated microRNAs in cancer. Curr Top Microbiol Immunol. 2010, 345: 47-70.PubMedGoogle Scholar
  11. Nallamshetty S, Chan SY, Loscalzo J: Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med. 2013, 64: 20-30.PubMed CentralPubMedView ArticleGoogle Scholar
  12. Gee HE, Ivan C, Calin GA, Ivan M: HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxid Redox Signal. 2013Google Scholar
  13. Chan SY, Loscalzo J: MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle. 2010, 9 (6): 1072-1083. 10.4161/cc.9.6.11006.PubMed CentralPubMedView ArticleGoogle Scholar
  14. Devlin C, Greco S, Martelli F, Ivan M: miR-210: More than a silent player in hypoxia. IUBMB life. 2011, 63 (2): 94-100.PubMed CentralPubMedGoogle Scholar
  15. Ivan M, Huang X: miR-210: Fine-Tuning the Hypoxic Response. Adv Exp Med Biol. 2014, 772: 205-227. 10.1007/978-1-4614-5915-6_10.PubMed CentralPubMedView ArticleGoogle Scholar
  16. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J: hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008, 14 (5): 1340-1348. 10.1158/1078-0432.CCR-07-1755.PubMedView ArticleGoogle Scholar
  17. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL: hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010, 116 (9): 2148-2158.PubMedGoogle Scholar
  18. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G, Zhang L: miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 2008, 7 (2): 255-264. 10.4161/cbt.7.2.5297.PubMed CentralPubMedView ArticleGoogle Scholar
  19. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ: Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009, 35 (6): 856-867. 10.1016/j.molcel.2009.09.006.PubMed CentralPubMedView ArticleGoogle Scholar
  20. Kelly TJ, Souza AL, Clish CB, Puigserver P: A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol. 2011, 31 (13): 2696-2706. 10.1128/MCB.01242-10.PubMed CentralPubMedView ArticleGoogle Scholar
  21. Nakada C, Tsukamoto Y, Matsuura K, Nguyen TL, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, Moriyama M: Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol. 2011, 224 (2): 280-288. 10.1002/path.2860.PubMedView ArticleGoogle Scholar
  22. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C: MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle. 2009, 8 (17): 2756-2768. 10.4161/cc.8.17.9387.PubMedView ArticleGoogle Scholar
  23. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE, Harris AL: miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer. 2013, 108 (5): 1133-1142. 10.1038/bjc.2013.56.PubMed CentralPubMedView ArticleGoogle Scholar
  24. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H: microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol. 2011, 301 (4): H1519-1530. 10.1152/ajpheart.01080.2010.PubMed CentralPubMedView ArticleGoogle Scholar
  25. Takikawa T, Masamune A, Hamada S, Nakano E, Yoshida N, Shimosegawa T: miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem Biophys Res Commun. 2013, 437 (3): 433-439. 10.1016/j.bbrc.2013.06.097.PubMedView ArticleGoogle Scholar
  26. Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2011, 286 (1): 420-428. 10.1074/jbc.M110.170852.PubMed CentralPubMedView ArticleGoogle Scholar
  27. Yang W, Sun T, Cao J, Liu F, Tian Y, Zhu W: Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res. 2012, 318 (8): 944-954. 10.1016/j.yexcr.2012.02.010.PubMedView ArticleGoogle Scholar
  28. Biswas S, Roy S, Banerjee J, Hussain SR, Khanna S, Meenakshisundaram G, Kuppusamy P, Friedman A, Sen CK: Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci U S A. 2010, 107 (15): 6976-6981. 10.1073/pnas.1001653107.PubMed CentralPubMedView ArticleGoogle Scholar
  29. He J, Wu J, Xu N, Xie W, Li M, Li J, Jiang Y, Yang BB, Zhang Y: MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res. 2013, 41 (1): 498-508. 10.1093/nar/gks995.PubMed CentralPubMedView ArticleGoogle Scholar
  30. Kim JH, Park SG, Song SY, Kim JK, Sung JH: Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis. 2013, 4: e588-10.1038/cddis.2013.117.PubMed CentralPubMedView ArticleGoogle Scholar
  31. Kim HW, Haider HK, Jiang S, Ashraf M: Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem. 2009, 284 (48): 33161-33168. 10.1074/jbc.M109.020925.PubMedView ArticleGoogle Scholar
  32. Gou D, Ramchandran R, Peng X, Yao L, Kang K, Sarkar J, Wang Z, Zhou G, Raj JU: miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol. 2012, 303 (8): L682-691. 10.1152/ajplung.00344.2011.PubMed CentralPubMedView ArticleGoogle Scholar
  33. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC: MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation. 2010, 122 (11 Suppl): S124-131.PubMed CentralPubMedView ArticleGoogle Scholar
  34. Chio CC, Lin JW, Cheng HA, Chiu WT, Wang YH, Wang JJ, Hsing CH, Chen RM: MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol. 2013, 87 (3): 459-468. 10.1007/s00204-012-0965-5.PubMedView ArticleGoogle Scholar
  35. Qiu J, Zhou XY, Zhou XG, Cheng R, Liu HY, Li Y: Neuroprotective effects of microRNA-210 against oxygen-glucose deprivation through inhibition of apoptosis in PC12 cells. Mol Med Rep. 2013, 7 (6): 1955-1959.PubMedGoogle Scholar
  36. Wang F, Xiong L, Huang X, Zhao T, Wu LY, Liu ZH, Ding X, Liu S, Wu Y, Zhao Y, Wu K, Zhu LL, Fan M: miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res. 2013, 11 (1): 657-667. 10.1016/j.scr.2013.04.005.PubMedView ArticleGoogle Scholar
  37. Mizuno Y, Tokuzawa Y, Ninomiya Y, Yagi K, Yatsuka-Kanesaki Y, Suda T, Fukuda T, Katagiri T, Kondoh Y, Amemiya T, Tashiro H, Okazaki Y: miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett. 2009, 583 (13): 2263-2268. 10.1016/j.febslet.2009.06.006.PubMedView ArticleGoogle Scholar
  38. Cicchillitti L, Di Stefano V, Isaia E, Crimaldi L, Fasanaro P, Ambrosino V, Antonini A, Capogrossi MC, Gaetano C, Piaggio G, Martelli F: Hypoxia-inducible factor 1-alpha induces miR-210 in normoxic differentiating myoblasts. J Biol Chem. 2012, 287 (53): 44761-44771. 10.1074/jbc.M112.421255.PubMed CentralPubMedView ArticleGoogle Scholar
  39. Gong Y, Xu F, Zhang L, Qian Y, Chen J, Huang H, Yu Y: MicroRNA expression signature for Satb2-induced osteogenic differentiation in bone marrow stromal cells. Mol Cell Biochem. 2014, 387: 227-239. 10.1007/s11010-013-1888-z.PubMedView ArticleGoogle Scholar
  40. Sarakul O, Vattanaviboon P, Tanaka Y, Fucharoen S, Abe Y, Svasti S, Umemura T: Enhanced erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol Dis. 2013, 51 (2): 98-103. 10.1016/j.bcmd.2013.03.005.PubMedView ArticleGoogle Scholar
  41. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008, 283 (23): 15878-15883. 10.1074/jbc.M800731200.PubMed CentralPubMedView ArticleGoogle Scholar
  42. Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, Yao J, Ding J, Bao M, Ge C, Yao M, Li J, He X: Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 2011, 54 (6): 2064-2075. 10.1002/hep.24614.PubMedView ArticleGoogle Scholar
  43. Alaiti MA, Ishikawa M, Masuda H, Simon DI, Jain MK, Asahara T, Costa MA: Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med. 2012, 16 (10): 2413-2421. 10.1111/j.1582-4934.2012.01557.x.PubMed CentralPubMedView ArticleGoogle Scholar
  44. Donnem T, Fenton CG, Lonvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes RM, Busund LT: MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One. 2012, 7 (1): e29671-10.1371/journal.pone.0029671.PubMed CentralPubMedView ArticleGoogle Scholar
  45. Liu F, Lou YL, Wu J, Ruan QF, Xie A, Guo F, Cui SP, Deng ZF, Wang Y: Upregulation of microRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Kidney Blood Press Res. 2012, 35 (3): 182-191. 10.1159/000331054.PubMedView ArticleGoogle Scholar
  46. Lou YL, Guo F, Liu F, Gao FL, Zhang PQ, Niu X, Guo SC, Yin JH, Wang Y, Deng ZF: miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol Cell Biochem. 2012, 370 (1–2): 45-51.PubMedView ArticleGoogle Scholar
  47. Shoji T, Nakasa T, Yamasaki K, Kodama A, Miyaki S, Niimoto T, Okuhara A, Kamei N, Adachi N, Ochi M: The effect of intra-articular injection of microRNA-210 on ligament healing in a rat model. Am J Sports Med. 2012, 40 (11): 2470-2478. 10.1177/0363546512458894.PubMedView ArticleGoogle Scholar
  48. Yamasaki K, Nakasa T, Miyaki S, Yamasaki T, Yasunaga Y, Ochi M: Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. J Orthop Res. 2012, 30 (8): 1263-1270. 10.1002/jor.22079.PubMedView ArticleGoogle Scholar
  49. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T: Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013, 288 (15): 10849-10859. 10.1074/jbc.M112.446831.PubMed CentralPubMedView ArticleGoogle Scholar
  50. Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH: Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013, 288 (48): 34343-34351. 10.1074/jbc.M113.480822.PubMed CentralPubMedView ArticleGoogle Scholar
  51. Zeng L, He X, Wang Y, Tang Y, Zheng C, Cai H, Liu J, Wang Y, Fu Y, Yang GY: MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain. Gene Ther. 2014, 21: 37-43. 10.1038/gt.2013.55.PubMedView ArticleGoogle Scholar
  52. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J: MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009, 10 (4): 273-284. 10.1016/j.cmet.2009.08.015.PubMed CentralPubMedView ArticleGoogle Scholar
  53. Chen Z, Li Y, Zhang H, Huang P, Luthra R: Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene. 2010, 29 (30): 4362-4368. 10.1038/onc.2010.193.PubMedView ArticleGoogle Scholar
  54. Favaro E, Ramachandran A, McCormick R, Gee H, Blancher C, Crosby M, Devlin C, Blick C, Buffa F, Li JL, Vojnovic B, Pires das Neves R, Glazer P, Iborra F, Ivan M, Ragoussis J, Harris AL: MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One. 2010, 5 (4): e10345-10.1371/journal.pone.0010345.PubMed CentralPubMedView ArticleGoogle Scholar
  55. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S, Magnone V, Ricci JE, Pouysségur J, Gounon P, Hofman P, Barbry P, Mari B: miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011, 18 (3): 465-478. 10.1038/cdd.2010.119.PubMed CentralPubMedView ArticleGoogle Scholar
  56. Colleoni F, Padmanabhan N, Yung HW, Watson ED, Cetin I, van Patot MC T, Burton GJ, Murray AJ: Suppression of mitochondrial electron transport chain function in the hypoxic human placenta: a role for miRNA-210 and protein synthesis inhibition. PLoS One. 2013, 8 (1): e55194-10.1371/journal.pone.0055194.PubMed CentralPubMedView ArticleGoogle Scholar
  57. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur J, Barbry P, Mazure NM, Mari B: MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013, 4: e544-10.1038/cddis.2013.71.PubMed CentralPubMedView ArticleGoogle Scholar
  58. Bertero T, Robbe-Sermesant K, Le Brigand K, Ponzio G, Pottier N, Rezzonico R, Mazure NM, Barbry P, Mari B: microRNAs target identification: lessons from hypoxamiRs. Antioxid Redox Signal. 2013Google Scholar
  59. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.PubMedView ArticleGoogle Scholar
  60. Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, Gui Y, Cai Z: Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One. 2012, 7 (12): e52280-10.1371/journal.pone.0052280.PubMed CentralPubMedView ArticleGoogle Scholar
  61. Fasanaro P, Romani S, Voellenkle C, Maimone B, Capogrossi MC, Martelli F: ROD1 is a seedless target gene of hypoxia-induced miR-210. PLoS One. 2012, 7 (9): e44651-10.1371/journal.pone.0044651.PubMed CentralPubMedView ArticleGoogle Scholar
  62. Yang W, Wei J, Sun T, Liu F: Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Radiat Oncol. 2013, 8: 102-10.1186/1748-717X-8-102.PubMed CentralPubMedView ArticleGoogle Scholar
  63. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y: MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 2006, 1: e116-10.1371/journal.pone.0000116.PubMed CentralPubMedView ArticleGoogle Scholar
  64. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Yla-Herttuala S: Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett. 2008, 582 (16): 2397-2401. 10.1016/j.febslet.2008.05.048.PubMedView ArticleGoogle Scholar
  65. Cann KL, Hicks GG: Regulation of the cellular DNA double-strand break response. Biochem Cell Biol. 2007, 85 (6): 663-674. 10.1139/O07-135.PubMedView ArticleGoogle Scholar
  66. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM: MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009, 69 (3): 1221-1229. 10.1158/0008-5472.CAN-08-2516.PubMed CentralPubMedView ArticleGoogle Scholar
  67. Okada H, Kohanbash G, Lotze MT: MicroRNAs in immune regulation–opportunities for cancer immunotherapy. Int J Biochem Cell Biol. 2010, 42 (8): 1256-1261. 10.1016/j.biocel.2010.02.002.PubMed CentralPubMedView ArticleGoogle Scholar
  68. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami-Chouaib F, Chouaib S: Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012, 72 (18): 4629-4641. 10.1158/0008-5472.CAN-12-1383.PubMedView ArticleGoogle Scholar
  69. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008, 8 (9): 705-713. 10.1038/nrc2468.PubMedView ArticleGoogle Scholar
  70. Elf SE, Chen J: Targeting glucose metabolism in patients with cancer. Cancer. 2014, 120: 774-780. 10.1002/cncr.28501.PubMed CentralPubMedView ArticleGoogle Scholar
  71. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702.PubMedView ArticleGoogle Scholar
  72. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce CM, Pastorino U, Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011, 108 (9): 3713-3718. 10.1073/pnas.1100048108.PubMed CentralPubMedView ArticleGoogle Scholar
  73. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chery L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M: Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One. 2013, 8 (7): e69239-10.1371/journal.pone.0069239.PubMed CentralPubMedView ArticleGoogle Scholar
  74. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006, 9 (3): 189-198. 10.1016/j.ccr.2006.01.025.PubMedView ArticleGoogle Scholar
  75. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H, Avivi C, Rosenblatt K, Polak-Charcon S, Ramon J, Rosenfeld N, Spector Y: Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn. 2010, 12 (5): 687-696. 10.2353/jmoldx.2010.090187.PubMed CentralPubMedView ArticleGoogle Scholar
  76. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F: MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol. 2010, 23 (4): 1229-1234.PubMedGoogle Scholar
  77. Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I, Rolland D, Salon C, Godfraind C, DeFraipont F, Dhobb M, Pelletier L, Wion D, Gay E, Berger F, Issartel JP: MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One. 2011, 6 (5): e20600-10.1371/journal.pone.0020600.PubMed CentralPubMedView ArticleGoogle Scholar
  78. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011, 10 (3): 507-517. 10.4161/cc.10.3.14754.PubMedView ArticleGoogle Scholar
  79. Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y, Yamashita H: High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 2012, 42 (4): 256-263. 10.1093/jjco/hys001.PubMedView ArticleGoogle Scholar
  80. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C: Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One. 2011, 6 (6): e20980-10.1371/journal.pone.0020980.PubMed CentralPubMedView ArticleGoogle Scholar
  81. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009, 2 (9): 807-813. 10.1158/1940-6207.CAPR-09-0094.View ArticleGoogle Scholar
  82. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H: Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010, 126 (1): 73-80. 10.1002/ijc.24687.PubMedView ArticleGoogle Scholar
  83. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, Voros D: Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2013, 42 (1): 67-71. 10.1097/MPA.0b013e3182592ba7.PubMedView ArticleGoogle Scholar
  84. Cho WC, Chow AS, Au JS: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009, 45 (12): 2197-2206. 10.1016/j.ejca.2009.04.039.PubMedView ArticleGoogle Scholar
  85. Miko E, Czimmerer Z, Csanky E, Boros G, Buslig J, Dezso B, Scholtz B: Differentially expressed microRNAs in small cell lung cancer. Exp Lung Res. 2009, 35 (8): 646-664. 10.3109/01902140902822312.PubMedView ArticleGoogle Scholar
  86. Xing L, Todd NW, Yu L, Fang H, Jiang F: Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol. 2010, 23 (8): 1157-1164. 10.1038/modpathol.2010.111.PubMedView ArticleGoogle Scholar
  87. Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT, Bremnes RM: Positive prognostic impact of miR-210 in non-small cell lung cancer. Lung Cancer. 2014, 83: 272-278. 10.1016/j.lungcan.2013.11.005.PubMedView ArticleGoogle Scholar
  88. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM: The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 2010, 8: 64-10.1186/1741-7015-8-64.PubMed CentralPubMedView ArticleGoogle Scholar
  89. Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O: MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 2013, 34 (1): 481-491. 10.1007/s13277-012-0573-2.PubMedView ArticleGoogle Scholar
  90. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008, 141 (5): 672-675. 10.1111/j.1365-2141.2008.07077.x.PubMedView ArticleGoogle Scholar
  91. Cai H, Lin L, Cai H, Tang M, Wang Z: Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol. 2013, 30 (2): 499-PubMedView ArticleGoogle Scholar
  92. Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, Li HC, Wu XN: Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 2013, 5 (5): 1639-1642.PubMed CentralPubMedGoogle Scholar
  93. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R: miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011, 15 (7): 1593-1602. 10.1111/j.1582-4934.2010.01148.x.PubMed CentralPubMedView ArticleGoogle Scholar
  94. Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M, Jiang F: Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011, 11: 374-10.1186/1471-2407-11-374.PubMed CentralPubMedView ArticleGoogle Scholar
  95. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 2011, 17 (21): 6802-6811. 10.1158/1078-0432.CCR-11-0419.PubMedView ArticleGoogle Scholar
  96. Ren Y, Gao J, Liu JQ, Wang XW, Gu JJ, Huang HJ, Gong YF, Li ZS: Differential signature of fecal microRNAs in patients with pancreatic cancer. Mol Med Rep. 2012, 6 (1): 201-209.PubMedGoogle Scholar
  97. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F: Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014, 140: 145-150. 10.1007/s00432-013-1555-5.PubMed CentralPubMedView ArticleGoogle Scholar
  98. Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB, Shao GG: Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer. J Int Med Res. 2013, 41 (5): 1437-1444. 10.1177/0300060513497560.PubMedView ArticleGoogle Scholar
  99. Zhao A, Li G, Peoc'h M, Genin C, Gigante M: Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013, 94 (1): 115-120. 10.1016/j.yexmp.2012.10.005.PubMedView ArticleGoogle Scholar
  100. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A: Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014, 44 (1): 53-58.PubMedGoogle Scholar
  101. Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, Jung K: Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem. 2010, 56 (6): 998-1006. 10.1373/clinchem.2009.141580.PubMedView ArticleGoogle Scholar
  102. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008, 105 (30): 10513-10518. 10.1073/pnas.0804549105.PubMed CentralPubMedView ArticleGoogle Scholar
  103. Ma R, Jiang T, Kang X: Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012, 31: 38-10.1186/1756-9966-31-38.PubMed CentralPubMedView ArticleGoogle Scholar
  104. Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschlager C, Holzhausen HJ, Wach S, Eckert AW, Taubert H: Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer. 2012, 130 (5): 1230-1235. 10.1002/ijc.26109.PubMedView ArticleGoogle Scholar
  105. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012, 109 (8): 3024-3029. 10.1073/pnas.1200010109.PubMed CentralPubMedView ArticleGoogle Scholar
  106. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y: Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013, 11: 10-10.1186/1479-5876-11-10.PubMed CentralPubMedView ArticleGoogle Scholar
  107. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011, 71 (17): 5635-5645. 10.1158/0008-5472.CAN-11-0489.PubMedView ArticleGoogle Scholar
  108. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE: Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol. 1998, 18 (5): 2845-2854.PubMed CentralPubMedView ArticleGoogle Scholar

Copyright

© Qin et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement